Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Coverage Initiated by Analysts at TD Cowen

Analysts at TD Cowen initiated coverage on shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) in a note issued to investors on Friday. The firm set a “buy” rating on the biotechnology company’s stock.

Other research analysts have also issued research reports about the company. Royal Bank Of Canada decreased their target price on Lakefront Biotherapeutics American Depositary Shares from $28.00 to $26.00 and set a “sector perform” rating on the stock in a research report on Tuesday, August 11th. Weiss Ratings lowered shares of Lakefront Biotherapeutics American Depositary Shares from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, August 4th. Wall Street Zen cut shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Morgan Stanley dropped their target price on shares of Lakefront Biotherapeutics American Depositary Shares from $30.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 11th. Finally, Zacks Research upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $30.67.

Lakefront Biotherapeutics American Depositary Shares Stock Down 3.7%

Shares of Lakefront Biotherapeutics American Depositary Shares stock opened at $28.27 on Friday. The firm has a market cap of $1.86 billion, a PE ratio of -20.05 and a beta of 0.27. Lakefront Biotherapeutics American Depositary Shares has a twelve month low of $25.68 and a twelve month high of $37.78. The business has a 50-day moving average price of $28.67 and a 200 day moving average price of $29.77.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last issued its quarterly earnings results on Monday, August 10th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $1.01. The business had revenue of $15.47 million for the quarter, compared to analysts’ expectations of $7.29 million. On average, sell-side analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -1.29 EPS for the current year.

Institutional Trading of Lakefront Biotherapeutics American Depositary Shares

A number of institutional investors have recently made changes to their positions in LKFT. ABC Arbitrage SA purchased a new stake in shares of Lakefront Biotherapeutics American Depositary Shares during the first quarter worth approximately $382,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in Lakefront Biotherapeutics American Depositary Shares in the 1st quarter valued at $248,000. QRG Capital Management Inc. boosted its stake in Lakefront Biotherapeutics American Depositary Shares by 21.9% during the 1st quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock worth $591,000 after purchasing an additional 3,535 shares during the last quarter. XTX Topco Ltd boosted its stake in Lakefront Biotherapeutics American Depositary Shares by 92.6% during the 4th quarter. XTX Topco Ltd now owns 23,219 shares of the biotechnology company’s stock worth $759,000 after purchasing an additional 11,162 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 121.9% during the fourth quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock worth $11,097,000 after buying an additional 186,452 shares in the last quarter. 32.46% of the stock is owned by institutional investors and hedge funds.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.